Persius/hicric huggingface dataset:
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state because the available language in the current Health Insurance Portability and Accountability 
Act (HIPAA) compliant code sets used to describe the pathology and laboratory categories and the tests 
included in those categories are not specific to the actual test results provided, all molecular diagnostic test 
(MDT) services must include an identifier as additional claim documentation. Test providers must receive an 
identifier specific to the applicable test and submit the test assigned identifier with the claim for 
reimbursement. The assigned identifier will provide a crosswalk between the tests associated detail 
information on file and the submitted claim detail line(s) required to adjudicate each tests claim. The unique 
identifier limits the need to submit the required additional information about the test on each claim. 
You can find these rules in the Local Coverage Determination (LCD) for MolDX: Molecular Diagnostic Tests 
(MDT), L35160. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
  
  The rules state that the following are documentation requirements for molecular pathology and genetic testing: 
1. All documentation must be maintained in the patient's medical record and made available to the 
contractor upon request. 
2. Every page of the record must be legible and include appropriate patient identification information (e.g., 
complete name, dates of service[s]). The documentation must include the legible signature of the physician or 
non-physician practitioner responsible for and providing the care to the patient. 
3. The submitted medical record must support the use of the selected ICD-10-CM code(s). The submitted 
CPT/HCPCS code must describe the service performed. 
4. In accordance with CFR Section 410.32, the medical record must contain documentation that the testing 
is expected to influence treatment of the condition toward which the testing is directed and will be used in the 
management of the beneficiary's specific medical problem. 
5. The medical record must support that the referring/ordering practitioner who ordered the test for a 
specific medical problem is treating the beneficiary for this specific medical problem. An example of 
documentation that could support the practitioners management of the beneficiarys specific medical problem 
would be at least two E/M visits performed by the ordering/referring practitioner over the previous six months. 
6. The medical record must include documentation of how the ordering/referring practitioner used the test 
results in the management of the beneficiarys specific medical problem. 
7. The ordering physician/nonphysician practitioner (NPP) documentation in the medical record must 
include, but is not limited to, history and physical or exam findings that support the decision making, 
problems/diagnoses, relevant data (e.g., lab testing, imaging results). 
8. The medical record from the ordering physician/NPP must clearly indicate all tests that are to be 
performed. 
9. Documentation requirements of the performing laboratory (when requested) include, but are not limited 
to, lab accreditation, test requisition, test record/procedures, reports (preliminary and final), and quality control 
record. 
 
You can find these rules in the Local Coverage Article Billing and Coding: Molecular Pathology and Genetic 
Testing, A58917. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract also says that virtual care, telehealth services are not covered out-of-network. You can find this 
information on page 123 of the Plan's 2022 Evidence of Coverage.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that the thermal radiofrequency destruction of cervical, thoracic, or lumbar paravertebral facet 
joint (median branch) nerves are considered medically reasonable and necessary for patients who meet ALL the 
following criteria: 
 
         Initial thermal RFA: 
             After the patient has had at least two (2) medically reasonable and necessary diagnostic MBBs, with 
each one providing a consistent minimum of 80% sustained relief of primary (index) pain (with the duration of 
relief being consistent with the agent used) AND 
            Repeat thermal facet joint RFA at the same anatomic site is considered medically reasonable and 
necessary provided the patient had a minimum of consistent 50% improvement in pain for at least six (6) 
months or at least 50% consistent improvement in the ability to perform previously painful movements and 
ADLs as compared to baseline measurement using the same scale; 
 
Frequency Limitation: For each covered spinal region no more than two (2) radiofrequency sessions will be 
reimbursed per rolling 12 months. 
 
You can find this information in Local Coverage Determination (LCD) Facet Joint Interventions for Pain 
Management L38765. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that plans may choose the networks of providers available to enrollees and may require enrollees 
to obtain authorization before receiving services. You can find this rule at 42 CFR Section 422.112(a) and in 
the Centers for Medicare and Medicaid Services, Internet Only Manual, Publication 100-16, Medicare 
Managed Care Manual, Chapter 1, Section 20.2. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract says that, with limited exceptions, members of the Plan must use network providers to get medical care 
and services. The only exceptions are emergencies, urgently needed care when the network is not available 
(generally, when the enrollee is out of the area), out-of-area dialysis services, and cases in which the Plan 
authorizes the use of out-of-network providers. You can find this information on page 44 of the Plan's 2022 
Evidence of Coverage. 
 
The Plan contract also says services that you get without prior authorization, when prior authorization is 
required for getting that service are not covered by our Plan. You can find this information on page 114 of the 
Plan's 2022 Evidence of Coverage.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that currently covered indications include using MRA for specific conditions to evaluate flow in 
internal carotid vessels of the head and neck, peripheral arteries of lower extremities, abdomen and pelvis, and 
the chest. Coverage is limited to MRA units that have received FDA premarket approval, and such units must 
be operated within the parameters specified by the approval. In addition, the services must be reasonable and 
necessary for the diagnosis or treatment of the specific patient involved. 
  
a. HEAD AND NECK 
Studies have proven that MRA is effective for evaluating flow in internal carotid vessels of the head and neck. 
However, not all potential applications of MRA have been shown to be reasonable and necessary. All of the 
following criteria must apply in order for Medicare to provide coverage for MRA of the head and neck:  
   MRA is used to evaluate the carotid arteries, the circle of Willis, the anterior, middle or posterior cerebral 
arteries, the vertebral or basilar arteries or the venous sinuses;  
   MRA is performed on patients with conditions of the head and neck for which surgery is anticipated and 
may be found to be appropriate based on the MRA. These conditions include, but are not limited to, tumor, 
aneurysms, vascular malformations, vascular occlusion or thrombosis. Within this broad category of disorders, 
medical necessity is the underlying determinant of the need for an MRA in specific diseases. The medical 
records should clearly justify and demonstrate the existence of medical necessity; and  
   MRA and CA are not expected to be performed on the same patient for diagnostic purposes prior to the 
application of anticipated therapy. Only one of these tests will be covered routinely unless the physician can 
demonstrate the medical need to perform both tests.  
 
While the intent of this policy is to provide reimbursement for either RA or CA, the Centers for Medicare & 
Medicaid Services (CMS) is also allowing flexibility for physicians to make appropriate decisions concerning 
the use of these tests based on the needs of individual patients. CMS anticipates, however, low utilization of the 
combined use of MRA and CA. Where indicated, evidence of the need to perform both MRA and CA is 
required. You can find this rule in the Medicare National Coverage Determinations Manual, Chapter 1, Section 
220.2(B)(2). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
The rules say that medically necessary services are those that are reasonable and necessary for the diagnosis or 
treatment of an illness or injury. Medically necessary services include services to improve the functioning of a 
malformed body member. You can find this rule in the Social Security Act, Section 1862(a)(1)(A). 
 
The rules say that Administration of continuous subcutaneous insulin for the treatment of diabetes mellitus 
(Refer to the ICD-10 code list in the LCD-related Policy Article for applicable diagnoses.) if criterion A or B is 
met and if criterion C or D is met:  
A. C-peptide testing requirement  must meet criterion 1 or 2 and criterion 3: 
1. C-peptide level is less than or equal to 110 percent of the lower limit of normal of the 
laboratory's measurement method. 
2. For beneficiaries with renal insufficiency and a creatinine clearance (actual or calculated 
from age, weight, and serum creatinine) less than or equal to 50 ml/minute, a fasting C-
peptide level is less than or equal to 200 per cent of the lower limit of normal of the 
laboratorys measurement method. 
3. A fasting blood sugar obtained at the same time as the C-peptide level is less than or 
equal to 225 mg/dl. 
B. Beta cell autoantibody test is positive. 
C. The beneficiary has completed a comprehensive diabetes education program, has been on a 
program of multiple daily injections of insulin (i.e., at least 3 injections per day) with frequent 
self-adjustments of insulin dose for at least 6 months prior to initiation of the insulin pump, and 
has documented frequency of glucose self-testing an average of at least 4 times per day during 
the 2 months prior to initiation of the insulin pump, and meets one or more of the following 
criteria (1 - 5) while on the multiple injection regimen:  
1. Glycosylated hemoglobin level (HbA1C) greater than 7 percent 
2. History of recurring hypoglycemia 
3. Wide fluctuations in blood glucose before mealtime 
4. Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dL 
5. History of severe glycemic excursions 
D. The beneficiary has been on an external insulin infusion pump prior to enrollment in Medicare 
and has documented frequency of glucose self-testing an average of at least 4 times per day 
during the month prior to Medicare enrollment.  Subcutaneous insulin is administered using ambulatory infusion pump E0784. You can find this rule in the 
Local Coverage Determination (LCD): External Infusion Pump L33794 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules state that all molecular diagnostic test (MDT) services must include an identifier as additional claim 
documentation. Test providers must receive an identifier specific to the applicable test and submit the test 
assigned identifier with the claim for reimbursement. The assigned identifier will provide a crosswalk between 
the tests associated detail information on file and the submitted claim detail line(s) required to adjudicate each 
tests claim. The unique identifier limits the need to submit the required additional information about the test 
on each claim. You can find this information in the Local Coverage Determination (LCD): MolDX: Molecular 
Diagnostic Tests (MDT) (L35160). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that Medicare will not pay for dental services. Dental services are items and services involving 
the care, treatment, filling, removal or replacement of teeth or structures directly supporting the teeth. Medicare 
defines "structures directly supporting the teeth" as the periodontium, which includes the gingivae, 
dentogingival junction, periodontal membrane, cementum of the teeth, and alveolar process. You can find this 
rule in the Social Security Act, Section 1862(a)(12) and in the Centers for Medicare and Medicaid Services, 
Internet Only Manual, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 150. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The contract 
says that the Plan covers certain dental services as a supplemental (extra) benefit. This benefit includes the 
requested item or service but is limited to one intraoral x-ray procedure code is covered at 100% per calendar 
year whenservices are rendered by an in-network provider. You can find this information in Chapter 4 on pages 
84-87 & 90-94 of the Plan's 2022 Evidence of Coverage (EOC).
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say a health plan must disclose to its enrollees in clear, accurate terms all cost sharing information 
(such as copayments, deductibles and coinsurance). You can find this rule at 42 CFR Section 422.111(a) and 
(b). 
 
The rules say that a copayment is a fixed amount charged to an enrollee on a per-service basis. The rules say 
that coinsurance is a fixed percentage of the total amount paid for a health care service that can be charged to 
an enrollee on a per-service basis. You can find this rule at 42 CFR Section 422.2. 
 
The rules say that Medicare will not pay for dental services. Dental services are items and services involving 
the care, treatment, filling, removal or replacement of teeth or structures directly supporting the teeth. Medicare 
defines "structures directly supporting the teeth" as the periodontium, which includes the gingivae, 
dentogingival junction, periodontal membrane, cementum of the teeth, and alveolar process. You can find this 
rule in the Social Security Act, Section 1862(a)(12) and in the Centers for Medicare and Medicaid Services, 
Internet Only Manual, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 150. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The contract 
says that the Plan covers certain dental services as a supplemental (extra) benefit. The Plan contract says that 
enrollees must pay a $425 copayment for a crown (D2750). The contract also says you have a $50 copayment 
for core build up (D2950). The contract says that you must pay a $15 copayment for prophylaxis (D1110). You 
can find this information on page 69 of the Plan's 2022 Evidence of Coverage (EOC).
Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101.

The rules say that Medicare may cover a drug or biological if it is safe and effective and otherwise reasonable and necessary. You can find this rule in the Centers for Medicare and Medicaid Services, Internet Only Manual, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 50.4.1.
 
Medicare rules also allow the plan to use step therapy. This is the process of beginning drug therapy for a medical condition with "preferred" (or more cost-effective) on-formulary drug alternative(s) and progressing to other drug therapies only as necessary. A plan must grant an exception to its step therapy rules if it determines that the requested drug is medically necessary, consistent with the prescriber's statement. The statement must show that the step therapy drugs: have been ineffective in treating the enrollee; or are likely to be ineffective or adversely affect the drug's effectiveness or patient compliance; or are likely to cause an adverse reaction or other harm to the enrollee. 

Medicare Advantage plans should ensure that new step therapy requirements do not disrupt ongoing Part B drug therapies for enrollees. Step therapy may only be applied to new prescriptions or administrations of Part B drugs for enrollees that are not actively receiving the affected medication. You can find this information at 42 CFR Sections 422.2 and 422.136.

If you want to read these Medicare rules, you can go to this website www.medicareappeal.com.

The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The contract says that the Plan has step therapy requirements for certain Medicare Part B covered drugs/biologicals. Enrollees may be required to try a preferred drug before the Plan will approve the requested medication. You can find this information on pages 94 to 95 of the Plan's 2022 Evidence of Coverage (EOC).
Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
Medicare does not pay for low vision aids. This exclusion includes all devices that use one or more lenses to 
aid vision or magnify images. This rule applies no matter the size, form or technological features of the device. 
This rule does not apply to:  
 
1. post-surgical prosthetic lenses after surgery in which the lens of the eye was removed;  
 
2. prosthetic intraocular lenses (IOLs) and one pair of conventional eyeglasses or contact lenses furnished after 
each cataract surgery with insertion of an IOL; and  
 
3. prosthetic lenses used by those who are lacking the natural lens of the eye and who were not furnished with 
an IOL.  
You can find this rule at 42 CFR Section 411.15(b). 
  
Medicare does not pay for eye exams for the purpose of prescribing, fitting, or changing eyeglasses or contact 
lenses for refractive error only. Medicare does not pay for procedures performed in the course of any eye exam 
to determine the refractive state of the eyes. Refractive procedures are not covered even when done in 
connection with otherwise covered diagnosis or treatment of illness or injury. You can find these rules at 42 
CFR Section 411.15(c).  
 
The rules say that a contract plan provider is an agent of the plan. Services and referrals obtained from a plan 
provider are viewed as plan-approved unless notice is given that the services will not be covered. When a plan 
provider gives, or refers an enrollee for, a service that the enrollee reasonably believes is covered by the plan, 
the enrollee is held harmless and need not pay more than the plan-allowed cost-sharing for that service.  
 
If a service is never covered by the plan and the plan's Evidence of Coverage (EOC) is clear that the service or 
item is never covered, the plan does not have to hold the enrollee harmless.  
 
For a service or item that is normally not covered, but could be covered under some conditions, the EOC alone 
is not adequate notice of non-coverage. If no notice of non-coverage is given, the enrollee is held harmless. 
You can find this rule in the Centers for Medicare and Medicaid Services, Internet Only Manual, Publication 
100-16, Medicare Managed Care Manual, Chapter 4, Section 160. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules. The Plan 
contract also says that the cover up to a $200 annual maximum toward the purchase of eyeglass lenses, frames, 
and contact lenses. You can find this information on pages 103-105 of the Plan's 2022 Evidence of Coverage.